{"id":"altb-268","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Fatigue"},{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Anemia"},{"rate":"5-10%","effect":"Thrombocytopenia"},{"rate":"5-10%","effect":"Neutropenia"},{"rate":"5-10%","effect":"Leukopenia"},{"rate":"5-10%","effect":"Anorexia"},{"rate":"5-10%","effect":"Weight loss"}]},"_chembl":{"chemblId":"CHEMBL3649220","moleculeType":"Small molecule","molecularWeight":"464.51"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By blocking the interaction between CD47 and SIRPα, ALTB-268 aims to prevent tumor cells from evading immune surveillance. This mechanism is thought to enhance the body's immune response against cancer cells.","oneSentence":"ALTB-268 is a small molecule inhibitor of the CD47/SIRPα axis.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T02:21:45.349Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory multiple myeloma"}]},"trialDetails":[{"nctId":"NCT07350577","phase":"PHASE1","title":"Evaluate the Safety, Tolerability, PK and PD of SAD of Intravenously Adminsterted ALTB-268 in Healthy Participants","status":"RECRUITING","sponsor":"AltruBio Inc.","startDate":"2025-11-17","conditions":"Ulcerative Colitis (UC)","enrollment":24},{"nctId":"NCT06109441","phase":"PHASE2","title":"Efficacy/Safety of ALTB-268 in Subjects w/Moderately to Severely Active UC Refractory to Biologics","status":"ACTIVE_NOT_RECRUITING","sponsor":"AltruBio Inc.","startDate":"2023-12-04","conditions":"Ulcerative Colitis","enrollment":50},{"nctId":"NCT05723692","phase":"PHASE1","title":"A First-In-Human SAD and MAD Study to Evaluate the Safety, Tolerability, PK and PD of SC Administered ALTB-268 in Healthy Volunteers","status":"COMPLETED","sponsor":"AltruBio Inc.","startDate":"2023-01-17","conditions":"Healthy Volunteers","enrollment":56}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"ALTB-268","genericName":"ALTB-268","companyName":"AltruBio Inc.","companyId":"altrubio-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"ALTB-268 is a small molecule inhibitor of the CD47/SIRPα axis. Used for Relapsed or refractory multiple myeloma.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}